

Editor's Note

This issue represents the final one for which I will serve as Editor-in-Chief. It has been my pleasure to work with an excellent group of Associate Editors (Joel Bockaert, Rocky Kass, John Lazo, Dianne Perez, Palmer Taylor, Robert Tukey, Gary Johnson [Associate Editor for Minireviews] and Joan Heller Brown [prior to this year]), the ASPET Board of Publications Trustees and editorial staff (Jill Filler [Managing Editor], Dan Collinge, Rich Dodenhoff, and others) in the ASPET Journals office in Bethesda.

The editing and publishing of *Molecular Pharmacology* has undergone a number of challenges and changes over the past several years. Two of the major ones have been the conversion to a fully electronic system for submission, editorial review, and publication and the concentration of editorial administration in the Bethesda office. I/we owe a special thanks to Maya Himawan, who ably administered and then closed the “pre-electronic” office at UCSD. Key developments of “our team” have been the expansion of the number and geographical distribution of Associate Editors, a substantial rise in number of submitted manuscripts, and expansion of the content of *Molecular Pharmacology* to include *Perspective* articles and more *Minireviews*. In parallel with these changes, my editorial colleagues and I have sought to retain the long-standing commitment of the journal to excellence with respect to timeliness, breadth of content, and quality. We are indebted to members of the Editorial Advisory Board (EAB) as well as non-EAB members for the considerable time and effort that each of them has devoted on behalf of *Molecular Pharmacology* and that have been critical for retaining—and hopefully improving—the journal's content.

Scientific journals exist as a forum for authors and readers to share discoveries and scientific insights, in the case of *Molecular Pharmacology* with a focus on mechanisms of drug action. I hope that we have facilitated this information exchange and through our efforts have advanced science and, ultimately, therapeutics. As the Associate Editors and I “exit the stage”, we offer Jeff Conn, the new Editor-in-Chief, and the editorial team that he assembles our best wishes for a long, successful “run”!

Paul A. Insel, M.D.
Editor